| 臺大學術典藏 |
2018-09-10T18:02:57Z |
Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units
|
Yeh, C.-Y. and Wang, F.-D. and Chuang, Y.-C. and Yang, C.-J. and Huang, S.-F. and Weng, W.-S. and Liaw, C.-H. and Sheng, W.-H.; WANG-HUEI SHENG; YU-CHUNG CHUANG |
| 臺大學術典藏 |
2021-02-26T01:59:20Z |
Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units
|
Yeh C.-Y.;Wang F.-D.;Chuang Y.-C.;Yang C.-J.;Huang S.-F.;Weng W.-S.;Liaw C.-H.;Wang-Huei Sheng; Yeh C.-Y.; Wang F.-D.; Chuang Y.-C.; Yang C.-J.; Huang S.-F.; Weng W.-S.; Liaw C.-H.; WANG-HUEI SHENG |
| 臺大學術典藏 |
2020-12-29T03:48:03Z |
Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units
|
Yeh C.-Y.;Wang F.-D.;Yu-Chung Chuang;Yang C.-J.;Huang S.-F.;Weng W.-S.;Liaw C.-H.;Sheng W.-H.; Yeh C.-Y.; Wang F.-D.; YU-CHUNG CHUANG; Yang C.-J.; Huang S.-F.; Weng W.-S.; Liaw C.-H.; Sheng W.-H. |
| 臺大學術典藏 |
2019-03-04T06:50:19Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yang, James Chih Hsin;Lin, Zhong Zhe;Lee, Jih Hsiang;Yang, Ching Yao;Lin, Yen Ting;Chen, Kuan-Yu;CHONG-JEN YU;JIN-YUAN SHIH;CHIA-LIN HSU;CHAO-CHI HO;WEI-YU LIAO;JIN-SHING CHEN; Lin, Yen Ting; JIN-SHING CHEN; WEI-YU LIAO; CHAO-CHI HO; CHIA-LIN HSU; Yang, Ching Yao; Chen, Kuan-Yu; Lee, Jih Hsiang; Lin, Zhong Zhe; JIN-YUAN SHIH; Yang, James Chih Hsin; Chong-Jen Yu |
| 臺大學術典藏 |
2020-03-30T08:50:44Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; Lin Y.-T.;Jin-Shing Chen;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; JIN-SHING CHEN; Liao W.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T01:32:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T;Chen J.-S;Liao W.-Y;Ho C.-C;Hsu C.-L;Yang C.-Y;Chen K.-Y;Lee J.-H;Lin Z.-Z;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Lin Y.-T; Chen J.-S; Liao W.-Y; Ho C.-C; Hsu C.-L; Yang C.-Y; Chen K.-Y; Lee J.-H; Lin Z.-Z; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:16Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:37Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Hsu C.-L.; CHAO-CHI HO; Liao W.-Y.; Chen J.-S.; Lin Y.-T.; Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Chao-Chi Ho;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T06:34:19Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU; Lin Y.-T.; Chen J.-S.; Liao W.-Y. |
| 臺大學術典藏 |
2020-08-13T06:33:27Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yang J.C.-H.; Yu C.-J.; JIN-YUAN SHIH; Lin Z.-Z.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:04Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Shih J.-Y.; Yang J.C.-H.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; WEI-YU LIAO; Chen J.-S.; Lin Y.-T. |
| 臺大學術典藏 |
2020-12-24T03:18:47Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Chia-Lin Hsu;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; CHIA-LIN HSU; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T02:38:31Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Anonymous |
| 臺大學術典藏 |
2021-07-13T06:04:31Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; LEE JIH-HSIANG; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:33Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; JIH-HSIANG LEE; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:51Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Kuan-Yu Chen;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; KUAN-YU CHEN; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-11T03:46:37Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-10T06:10:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T06:59:53Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L; Yang J.C.-H; Lu S.-H; Lin Z.-Z; Yu C.-J; Yang W.-C; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Chong-Jen Yu;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; CHONG-JEN YU; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L.; Yang J.C.-H.; Lu S.-H.; Lin Z.-Z.; Yu C.-J.; JIN-YUAN SHIH; Chen Y.-H.; Hsu F.-M.; Yang W.-C.; Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Jin-Yuan Shih;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H. |
| 臺大學術典藏 |
2021-02-23T08:26:10Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Sung-Hsin Kuo; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Chih-Hsin Yang;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; CHIH-HSIN YANG; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-07-02T03:21:35Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
WEN-CHI YANG; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-11T03:46:34Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; ZHONG-ZHE LIN; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2022-06-10T06:10:55Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; ZHONG-ZHE LIN; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2022-06-27T06:59:44Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; CHONG-JEN YU; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2018-09-10T15:28:24Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
Chang, T.-C. and Hsiao, S.-M. and Chen, C.-H. and Wu, W.-Y. and Lin, H.-H.; HO-HSIUNG LIN; CHI-HAU CHEN |
| 臺大學術典藏 |
2020-01-22T08:53:05Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
Chang T.-C.; Hsiao S.-M.; CHI-HAU CHEN; Wu W.-Y.; Lin H.-H. |
| 臺大學術典藏 |
2020-02-17T05:28:09Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
TING-CHEN CHANG; Hsiao S.-M; Chen C.-H; Wu W.-Y; Lin H.-H. |
| 臺大學術典藏 |
2020-02-17T08:50:54Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
Chang T.-C; Hsiao S.-M; Chen C.-H; Wu W.-Y; HO-HSIUNG LIN |
| 臺大學術典藏 |
2021-03-03T03:00:58Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
Chang T.-C.; Hsiao S.-M.; Chen C.-H.; Wu W.-Y.; HO-HSIUNG LIN |
| 國立臺灣大學 |
2014 |
Clinical outcomes following sublaminar-trimming laminoplasty for extensive lumbar canal stenosis
|
Liu, Wen-Jiunn; Hong, Shih-Wun; Liou, Da-Yon; Lu, Tung-Wu; 呂東武 |
| 臺大學術典藏 |
2020-02-26T01:37:11Z |
Clinical outcomes following sublaminar-trimming laminoplasty for extensive lumbar canal stenosis
|
Liu, W.-J.; Hong, S.-W.; Liou, D.-Y.; Lu, T.-W.; TUNG-WU LU |
| 臺大學術典藏 |
2016 |
Clinical Outcomes Following Transcatheter Aortic Valve Replacement in Asian Population
|
Kim H.-S.; Kozuma K.; Lee S.-W.; Kim Y.-H.; Lee C.W.; Park S.-W.; Muramatsu T.; Hanyu M.; Kang S.-J.; Park D.-W.; Park J.-B.; MAO-HSIN LIN; Arai T.; Yamanaka F.; Araki M.; Tay E.; Lee M.K.-Y.; Yin W.-H.; Kao H.-L.; Shirai S.; Watanabe Y.; Hayashida K.; Ahn J.-M.; Yoon S.-H.; Saito S.; Park S.-J.; Asian TAVR Investigators |
| 臺大學術典藏 |
2016 |
Clinical Outcomes Following Transcatheter Aortic Valve Replacement in Asian Population
|
Lee C.W.; Park S.-W.; Muramatsu T.; Hanyu M.; Kozuma K.; Kim H.-S.; Saito S.; Park S.-J.; Asian TAVR Investigators; Yoon S.-H.; Ahn J.-M.; Hayashida K.; Watanabe Y.; Shirai S.; HSIEN-LI KAO; Yin W.-H.; Lee M.K.-Y.; Tay E.; Araki M.; Yamanaka F.; Arai T.; Lin M.-S.; Park J.-B.; Park D.-W.; Kang S.-J.; Lee S.-W.; Kim Y.-H. |
| 臺大學術典藏 |
2016 |
Clinical Outcomes Following Transcatheter Aortic Valve Replacement in Asian Population
|
Kim Y.-H.; Lee S.-W.; Kang S.-J.; Park D.-W.; Park J.-B.; Lin M.-S.; Arai T.; Yamanaka F.; Araki M.; Tay E.; Lee M.K.-Y.; Yin W.-H.; Yoon S.-H.; Ahn J.-M.; Hayashida K.; Watanabe Y.; Shirai S.; HSIEN-LI KAO; Asian TAVR Investigators; Park S.-J.; Lee C.W.; Park S.-W.; Muramatsu T.; Hanyu M.; Kozuma K.; Kim H.-S.; Saito S. |
| 臺大學術典藏 |
2021-08-24T06:14:56Z |
Clinical Outcomes Following Transcatheter Aortic Valve Replacement in Asian Population
|
Anonymous |
| 臺大學術典藏 |
2021-08-24T06:21:20Z |
Clinical Outcomes Following Transcatheter Aortic Valve Replacement in Asian Population
|
Yoon S.-H.; Ahn J.-M.; Hayashida K.; Watanabe Y.; Shirai S.; Kao H.-L.; Yin W.-H.; Lee M.K.-Y.; Tay E.; Araki M.; Yamanaka F.; Arai T.; MAO-SHIN LIN; Park J.-B.; Park D.-W.; Kang S.-J.; Lee S.-W.; Kim Y.-H.; Lee C.W.; Park S.-W.; Muramatsu T.; Hanyu M.; Kozuma K.; Kim H.-S.; Saito S.; Park S.-J.; Asian TAVR Investigators |
| 臺大學術典藏 |
2022-04-14T23:27:31Z |
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens
|
WEI-LI MA; Chia-Chi Lin; FENG-MING HSU; JANG-MING LEE; JIN-SHING CHEN; Huang, Yen Lin; YIH-LEONG CHANG; Chang, Chin Hao; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-03-29 |
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens
|
Yang, James Chih-Hsin; Chang, Chin-Hao; Chang, Yih-Leong; Huang, Yen-Lin; Chen, Jin-Shing; Lee, Jang-Ming; Feng-Ming Hsu; Lin, Chia-Chi; MA, WEI-LI |
| 臺大學術典藏 |
2022-07-26T08:09:28Z |
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens
|
Ma W.-L.; Lin C.-C.; Hsu F.-M.; Lee J.-M.; Chen J.-S.; Huang Y.-L.; YIH-LEONG CHANG; Chang C.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-08-03T05:16:42Z |
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens
|
Ma, Wei-Li; Lin, Chia-Chi; Feng-Ming Hsu; Lee, Jang-Ming; Chen, Jin-Shing; YEN-LIN HUANG; Chang, Yih-Leong; Chang, Chin-Hao; Yang, James Chih-Hsin |
| 國立臺灣大學 |
2015 |
Clinical Outcomes for Teeth Treated with Electrospun Poly(epsilon-caprolactone) Fiber Meshes/Mineral Trioxide Aggregate Direct Pulp Capping
|
Lee, Li-Wan; Hsiao, Sheng-Huang; Hung, Wei-Chiang; Lin, Yun-Ho; Chen, Po-Yu; Chiang, Chun-Pin; ���T�y |
| 臺大學術典藏 |
2020-12-28T08:09:27Z |
Clinical outcomes from out-of-hospital cardiac arrest in low-resource settings — A scoping review
|
Lauridsen K.G.; Bray J.; Breckwoldt J.; Greif R.; Finn J.C.; Garg R.; Bigham B.L.; Cheng A.; Schlieber J.; Semeraro F.; Monsieurs K.G.; Schnaubelt S.; Schnaubelt S.;Monsieurs K.G.;Semeraro F.;Schlieber J.;Cheng A.;Bigham B.L.;Garg R.;Finn J.C.;Greif R.;Bray J.;Breckwoldt J.;Lauridsen K.G.;Lockey A.;Gilfoyle E.;Ming-Ju Hsieh;Ma M.H.-M.;Pellegrino J.L.;Yeung J.; Lockey A.; Gilfoyle E.; MING-JU HSIEH; Ma M.H.-M.; Pellegrino J.L.; Yeung J. |
| 臺大學術典藏 |
2020 |
Clinical outcomes from out-of-hospital cardiac arrest in low-resource settings — A scoping review
|
Schnaubelt S.; Monsieurs K.G.; Semeraro F.; Schlieber J.; Cheng A.; Bigham B.L.; Garg R.; Finn J.C.; Greif R.; Bray J.; Breckwoldt J.; Lauridsen K.G.; Lockey A.; Gilfoyle E.; Hsieh M.-J.; MATTHEW HUEI-MING MA; Pellegrino J.L.; Yeung J. |
